Peptide binding specificities of HLA-B*5701 and B*5801

Science China Life Sciences

Volumn 55, Issue 9, 2012, Pages 818-825

  Zhang, YaLan ^a   Mei, Hu ^a   Wang, Qing ^a   Xie, JiangAn ^a   Lv, Juan ^a   Pan, XianChao ^a   Tan, Wen ^a  

^a CHONGQING UNIVERSITY   (China)

Author keywords

B*5701; B*5801; human leukocyte antigen; P I concept; SVM; VHSE

Indexed keywords

EID: 84867122119     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-012-4374-z     Document Type: Article

References (25)

1. Park B K, Pirmohamed M, Kitteringham N R. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol, 1998, 11: 969-988.
2. Naisbitt D J, Gordon S, Pirmohamed M, et al. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf, 2000, 23: 483-507.
3. Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis, 2006, 43: 99-102.
4. Hetherington S, Hughes A R, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet, 2002, 359: 1121-1122.
5. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 2002, 359: 727-732.
6. Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther, 2002, 24: 565-573.
7. Chessman D, Lethborg T, Kostenko L, et al. Abacavir hypersensitivity in HLA-B57-positive individuals with HIV infection is dependent upon the conventional MHC-I Ag presentation pathway. Tissue Antigens, 2007, 69: 373-373.
8. Martin A M, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B* 5701 and a haplotypic Hsp70-Hom variant. Pnas, 2004, 101: 4180-4185.
9. Gerber B O, Pichler W J. Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions. AAPS J, 2006, 8: 160-165.
10. Posadas S, Pichler W. Delayed drug hypersensitivity reactions-new concepts. Clin Exp Allergy, 2007, 37: 989-999.
11. Rozieres A, Vocanson M, Saïd B B, et al. Role of T cells in nonimmediate allergic drug reactions. Curr Opin Allergy Cl, 2009, 9: 305-310.
12. Chung W H, Hung S I, Chen Y T. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Cl, 2007, 7: 317-323.
13. Adam J, Eriksson K K, Schnyder B, et al. Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J Immunol, 2012, 1-11.
14. + T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity, 2008, 28: 822-832.
15. Bharadwaj M, Illing P, Kostenko L. Personalized medicine for HLA-associated drug-hypersensitivity reactions. Pers Med, 2010, 7: 495-516.
16. Trybula W J. Data mining and knowledge discovery. Annu Rev Inform Sci, 1997, 32: 197-229.
17. Vita R, Zarebski L, Greenbaum J A, et al. The immune epitope database 2. 0. Nucleic Acids Res, 2010, 38: D854-D862.
18. Sathiamurthy M, Peters B, Bui H H, et al. An ontology for immune epitopes: application to the design of a broad scope database of immune reactivities. Immunome Res, 2005, 1: 1-10.
19. Mei H, Liao Z H, Zhou Y, et al. A new set of amino acid descriptors and its application in peptide QSARs. Biopolymers, 2005, 80: 775-786.
20. Sanchez A, David V. Advanced support vector machines and kernel methods. Neurocomputing, 2003, 55: 5-20.
21. Schölkopf B, Smola A J. Learning with Kernels: Support Vector Machines, Regularization, Optimization, and Beyond. Boston: The Mit Press, 2001.
22. Tian F, Yang L, Lv F, et al. In silico quantitative prediction of peptides binding affinity to human MHC molecule: an intuitive quantitative structure-activity relationship approach. Amino Acids, 2009, 36: 535-554.
23. Li Z L, Li G R, Shu M, et al. A novel vector of topological and structural information for amino acids and its QSAR applications for peptides and analogues. Sci China Ser B-Chem, 2008, 51: 946-957.
24. Mei H, Zhou Y, Liao Z H, et al. Study on quantitative structure-activity relationships of HLA-A* 0201 restrictive CTL epitopes. Acta Chim Sin, 2006, 64: 949-952.
25. Guan P, Doytchinova I A, Walshe V A, et al. Analysis of peptide-protein binding using amino acid descriptors: prediction and experimental verification for human histocompatibility complex HLA-A*0201. J Med Chem, 2005, 48: 7418-7425.